MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1

US8754046B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Rong Wang · Mianyang, CN
• Steven A. Rosenberg · Potomac, US
• Gang Zeng · Germantown, US

Key dates

• Filing date: Sep 28, 2009
• Grant date: Jun 17, 2014
• Expiry date: Sep 28, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.